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Genetic differences (polymorphisms) among members of a population are thought to influence
susceptibility to various environmental exposures. In practice, however, this information is
rarely incorporated into quantitative risk assessment and risk management. We describe an an-
alytic framework for predicting the risk reduction and value-of-information (VOI) resulting
from specific risk management applications of genetic biomarkers, and we apply the frame-
work to the example of occupational chronic beryllium disease (CBD), an immune-mediated





1*0201, contains a substitution of glutamate for lysine at position 69 that appears to








70%) with respect to CBD among indi-
viduals occupationally exposed to respirable beryllium. The expected postintervention CBD
prevalence rates for using the genetic variant (1) as a required job placement screen, (2) as
a medical screen for semiannual in place of annual lymphocyte proliferation testing, or (3) as a
voluntary job placement screen are 0.08%, 0.8%, and 0.6%, respectively, in a hypothetical co-
hort with 1% baseline CBD prevalence. VOI analysis is used to examine the reduction in total
social cost, calculated as the net value of disease reduction and financial expenditures, expected
for proposed CBD intervention programs based on the genetic susceptibility test. For the ex-
ample cohort, the expected net VOI per beryllium worker for genetically based testing and in-
tervention is $13,000, $1,800, and $5,100, respectively, based on a health valuation of $1.45 mil-
lion per CBD case avoided. VOI results for alternative CBD valuations are also presented.
Despite large parameter uncertainty, probabilistic analysis predicts generally positive utility for
each of the three evaluated programs when avoidance of a CBD case is valued at $1 million or
higher. Although the utility of a proposed risk management program may be evaluated solely
in terms of risk reduction and financial costs, decisions about genetic testing and program im-
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Biomarkers have the potential to refine many
toxicological risk assessment model parameters,
thereby reducing uncertainty regarding individual
and population risk. Although exposure biomarkers
have been used in risk assessment for some time, and
clinical effect biomarkers have long been part of med-






with the practical application of biomarkers of sus-





are particularly underused in legitimate disease pre-
vention, partly because of the controversial nature of
their use and partly because of complexities in judg-
ing their practical utility.
In this article, we use risk assessment techniques
to estimate the potential disease reduction among be-
ryllium workers from the proposed use of relevant
genetic information. In particular, we estimate the
impact of proposed screening programs and height-
ened medical surveillance based on screening beryl-
lium workers for a genetic polymorphism at position


















 to assess the
net social benefits derived from using individual ge-
netic information to identify and protect susceptible
individuals. Clearly the usefulness of genetic infor-
mation depends on a number of legal, ethical, and
social factors. We briefly address the implications of
these factors, as well as the costs and occupational
health implications of genetic screening using the
Glu-69 test. Model calculations are conducted by using




Beryllium is a rare metal primarily used in the
ceramics, aircraft, and nuclear industries during the last
half-century, though recent reports indicate new ap-





 Respirable beryllium parti-
cles are toxic to humans; they cause pneumonitis
(acute beryllium disease) at high exposures and chronic
beryllium disease (CBD) at lower exposures. CBD is
generally characterized by diffuse interstitial infiltra-
tion, alveolitis, and fibrosis and often involves devel-
opment of granulomas. Beryllium-induced granulo-
mas are histologically indistinguishable from those










 Though beryllium diseases including can-
cer and acute beryllium disease are generally associ-
ated with pulmonary dysfunction, other organs, in-
cluding the lymphatic system, heart, skin, liver, and













 in air was implemented by the U.S. Atomic Energy
Commission, acute beryllium disease was essentially
eliminated in the U.S. but the incidence of CBD con-
tinued unabated. The Occupational Safety and Health
Administration (OSHA) later adopted and currently








 standard. CBD, however, is still
prevalent among workers exposed to beryllium dusts,












The overall prevalence rate of CBD among indi-
viduals known to have worked in beryllium-contami-





beryllium workers routinely engaged in certain work
tasks, such as machining and ceramics dry pressing,




though associated median daily weighted average be-
ryllium air concentrations were below the OSHA
standard. Though the “beryllium worker” character-
ization varies from study to study, most studies now
include administrators, engineers, janitors, and other
nonmachinists if they are known to have regularly
been present in buildings with ongoing or previous
beryllium use or potential exposure. Cases of CBD










 despite their lack
of direct involvement in high-risk activities.
A beryllium worker health surveillance program
was instituted at the beginning of the decade at the
U.S. Department of Energy (DOE) Oak Ridge Y-12
Plant and the Rocky Flats Environmental Technol-
ogy Site. The program now includes dozens of other
DOE sites where beryllium was used and has identi-
fied approximately 9,000 workers with potential pre-





posure reductions to levels generally at or below the
OSHA standard, roughly 1% of beryllium-exposed




The similar pathogenesis of CBD to other pul-
monary granulomatous diseases, including sarcoido-
sis, and available animal-based experimental data
suggest that susceptibility to CBD involves a genetic
component. Although a number of genetic polymor-
phisms have been investigated to identify potential
associations with CBD, the presence of a glutamate














 and has been suggested as a poten-





 Human Leukocyte Antigen (HLA) genes
are a group of genes similar to Major Histocompat-
ability Complex genes found in other species. Certain
HLA genes located in the D-region on the short arm

















produce tetrameric proteins involved in antigen rec-
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ognition that bind to endocytosed fragments such as
beryllium. Polymorphisms in the beta chains are





Another screening biomarker is the beryllium
lymphocyte proliferation test (LPT), for which a pos-
itive result indicates immunologic sensitization to be-
ryllium and heightened susceptibility to CBD. This in
vitro assay consists of an evaluation of the prolifera-
tive response of isolated lymphoctyes to the presence
of beryllium. A positive LPT result is considered a
sign of immunologic sensitization to beryllium and is




 At DOE sites, beryllium
workers are currently tested with the LPT every 1 to
3 years. Sensitized workers (as indicated by a con-
firmed positive LPT) are reassigned to jobs without
beryllium exposure and followed up with additional






In the present analysis we use risk assessment
techniques to assess the impact of using the Glu-69
test as a placement or medical screen for occupa-
tional beryllium exposure. One proposed interven-





) workers from beryllium-contaminated
areas, which might require job reassignment. This in-
tervention could be required or strictly voluntary.
Another option is more aggressive medical monitor-
ing for genetically susceptible individuals. This might
consist of more frequent LPT, physical examinations,





 individuals might be a rea-
sonable intervention strategy for CBD because indi-
viduals in the early stages of disease would be identi-
fied more quickly, thereby allowing rapid removal
from further exposure to beryllium and earlier treat-
ment where warranted.
We evaluate three specific examples of Glu-
69-based risk management options: (1) required
screening of workers for job placement in beryl-
lium-contaminated areas, (2) increased frequency of





workers from annual to semiannual testing, and (3)
voluntary genetic testing and informed decison
making by workers with potential beryllium expo-
sure. The expected reduction in CBD risk and the
implementation cost per person are estimated for
each of these three genetic interventions by using
distributional analysis. We generated 20,000 simple
random samples for each variable during Monte
Carlo simulation.
 
3.1. CBD Risk Model
 
For risk management using binary susceptibil-
ity biomarkers such as Glu-69, the expected post-






) is the population-
weighted average of the CBD risk among those





and the post-intervention CBD risk among workers








































Conditional disease probabilities are often written as
sensitivity, specificity, or predictive value (see Appen-

































































Preplacement occupational screening is one ge-
netically based risk management option. This type of
risk management program relies on changing the
proportion of workers with genetic susceptibility,


















being removed through screening, the post-screening


























































































































), indicates the post-




 workers. Eq. 2 can
therefore be rewritten as:
(3)
We use Eq. 3 to predict the risk reduction at-
tained through various genetically based risk man-













dent on the baseline prevalence of disease, they can
be directly observed only in cohort studies. However,
if the baseline prevalence is known or assumed, the
sensitivity and specificity from case-control studies
may be used to estimate predictive values as de-




 We assume that
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CBD are constant with respect to baseline preva-
lence and use the three parameters to estimate PV1
and PV2 as described in the Appendix.
3.2. Glu-69 VOI Model
Analysis of the expected costs and benefits associ-
ated with a risk management option provides informa-
tion that is useful for rational decison making. Value-
of-information (VOI) analysis is used to estimate the
impact of new data on the net social costs or opportu-
nity loss associated with a decision.(5,18,19) We have cho-
sen to evaluate VOI for each Glu-69-based risk man-
agement program in the context of its predicted effect
on expected total social cost (TSC). The TSC expresses
the net value of the health impacts and financial costs
associated with a health risk management alternative:
TSC 5 FC 1 rpBd (4)
where FC is the per capita financial cost of program
implementation, including administrative costs, bio-
marker sampling and laboratory analysis costs, and
any other expenses, and Bd is the health cost associ-
ated with each case of CBD. Broader social or legal
costs associated with each genetic intervention are
not included in our evaluation of TSC but could be
added to Eq. 4 if desired.(5) The cost per beryllium
worker of voluntary screening is related to the cost of
genetic testing for each job applicant (Cgenotype) and the
cost of genetic counseling for each Glu-691 job appli-
cant (Ccounsel) by the following equation:
(5)
We set Ccounsel to 0 for required preplacement screen-
ing because we assume that genetic counseling would
not be necessary in this case. Eq. 5 assumes that all
job applicants will undergo genetic testing but only
Glu-691 individuals will require counseling. If all
Glu-692 and Glu-691 individuals are to be counseled,
f is removed from the numerator of Eq. 5. In the base-
line case, where no susceptibility biomarker informa-
tion is collected and no control strategy is imple-
mented, FC 5 0 and rp 5 p.
The cost per beryllium worker of a genetically tar-
geted LPT frequency increase is the sum of the cost of
genetic testing for each worker (Cgenotype) and the cost of
additional LPTs for each Glu-691 worker (CLPT):
FC 5 Cgenotype 1 fCLPT (6)





slightly more frequent hiring associated with the LPT
based genetic intervention, though this is an expected
result of earlier detection and removal of sensitized
workers. The effect on costs is assumed to be negligi-
ble for the case presented here.
VOI expresses the predicted degree to which a
Glu-69-based CBD intervention program mitigates
total social impacts:
VOI 5 TSCbaseline 2 TSCoption (7)
where TSCoption is the total social cost for the specified
risk management option and TSCbaseline is the total so-
cial cost for the baseline option (i.e., no testing for
Glu-69). The most cost-effective risk management
option is that which maximizes VOI.
3.3. Characterization of Input Variables
Because many of the parameters used to calcu-
late VOI are uncertain, we apply probabilistic uncer-
tainty analysis using Monte Carlo simulation tech-
niques.(20) In earlier work, we assigned point estimates
and plausible bounds for each parameter and used
them to calculate a best estimate and plausible range
of VOI for the Glu-69 test in each risk management
program.(21) Here we estimate the likelihood of all
possible values for most model parameters by using
subjective probability distributions (Table I) in com-
bination with fixed prevalence rates and fixed CBD
avoidance values. The basis for each of these esti-
mates is described in the following section.
Variables treated as uncertain in this analysis in-
clude the sensitivity and specificity of the Glu-69 test,
the cost per LPT and cost per Glu-69 test, the impact
of early LPT detection of sensitization on CBD pro-
gression, and the proportion of workers in the volun-
tary screening program who decide to remove them-
selves from exposure if test results indicate genetic
susceptibility (i.e., Glu-691).
3.3.1. CBD Prevalence; Sensitivity and Specificity 
to Glu-69
The value of Glu-69 testing, or any other type of
genetic testing, depends on the prevalence of disease
in the target population. The prevalence of CBD
among beryllium workers is reported to be about 1%
to 16% depending upon specific job task,(16) and 1% to
5% averaged among all beryllium workers.(22) We re-
peat the CBD risk and VOI calculations over a range
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of potential baseline prevalence rates. Thus, for any
specific beryllium-exposed worker cohort, the pre-
dicted risk reduction and VOI can be determined by
using the baseline CBD prevalence.
The first study to correlate HLA polymorphisms
with CBD status found that 97% of CBD-positive be-
ryllium workers had Glu-691 (n 5 33) but that only
70% of CBD negative beryllium workers were Glu-
692 (n 5 44).(2) A more recent cohort study by the
same principal investigator found Glu-69 sensitivity
and specificity rates of 83% and 70%, respectively,
among 6 CBD cases and 121 controls.(23) Because the
cohort study had very few cases of disease, the lower
estimated sensitivity rate derived from that study
has a very wide confidence interval and is statisti-
cally indistinguishable from the estimates derived
from the original study. We chose to use the case-
control study as a basis for selecting the sensitivity
and specificity rates for our model. On the basis of
the conditional likelihood of the sensitivity and
specificity rates given the observed binomial varia-
tion, we represent the uncertainty in those rates
with beta distributions (Table I).
3.3.2. Value of CBD Avoidance; Cost of Glu-69 
Screening and LPT Testing
Bd indicates the economic preference for avoid-
ing a single case of CBD and is typically determined
by using “cost of illness” (COI) approaches, “willing-
ness to pay” (WTP) measures, or other methods.(24)
COI estimates are obtained by disaggregation of di-
rect and indirect costs (e.g., health care costs and lost
wages). COI estimates underestimate the societal
value of disease avoidance because they place no value
on lost time other than for wage losses. Though they
also fail to value pain and suffering associated with dis-
ease, COI techniques are useful for initially estimating
the value of disease avoidance. WTP approaches im-
plicitly include pain and suffering as well as the COI.
In practice, health valuation estimates vary
considerably according to the methods and assump-
tions chosen. The choice of valuation method and
discount rate strongly influence the final valuation.
We select a variety of estimates based on different
approaches and repeat the risk and VOI calculations
for each estimate.
We obtain a low estimate of the COI for CBD
based on the medical cost savings per CBD case
avoided according to a DOE economic analysis.(25)
The mean valuation for the four potential treatment
scenarios in that analysis is $12,200. This valuation
uses a discount rate of 7% and assumes that workers
are diagnosed with CBD at age 40 and live to age 70.
A second COI estimate(21) is based on reported treat-
ment costs and lost wages for general respiratory dis-
eases. For this estimate we assumed 45 years would
be spent with reduced activity and extended the daily
respiratory disease costs throughout that entire pe-
riod without discounting to obtain an expected value
of $1,450,000 per case of CBD avoided. With a 5-year
latency and a 7% discount rate, this value is reduced
to approximately $290,000 per CBD case. We evalu-
ate the results by using both the discounted and non-
discounted values (Table I).
Table I. Input Parameters for Glu-69 Value-of-Information Model
Parameter Description Valuea Confidenceb
Sn Sensitivity of Glu-69 for CBD prediction b(33, 2) High
Sp Specificity of Glu-69 for CBD prediction b(32, 14) High
Bd Statistical value of CBD ($million/case) Various (see Table III) Low
Cgenotype Cost of Glu-69 testing ($/applicant) T(100, 150, 500) Medium
CLPT Present value of costs of increased LPT frequency ($/Glu-691 worker) U(700, 2,200) Medium
Ccounsel Cost of genetic counseling ($/Glu-691 applicant) T(50, 100, 200) Medium
wscreen Removal probability for a Glu-691 worker for required screening 100% High
wLPT Removal probability for a Glu-691 worker for increased LPT frequency 0% Medium
wvolunteer Removal probability for a Glu-691 worker for voluntary screening U(0%, 100%) Medium
escreen Risk reduction efficacy (for a Glu-691 worker) of required screening 0% High
eLPT Risk reduction efficacy (for a Glu-691 worker) of increased LPT frequency T(0%, 5%, 50%) Low
evolunteer Risk reduction efficacy (for a Glu-691 worker) of voluntary screening 0% Medium
a b(v,w) indicates a beta distribution, U(l,u) indicates a uniform distribution, and T(l,m,u) indicates a triangular distribution. Values are as-
signed on the basis of empirical evidence, theoretical models, and judgment.
b Confidence indicates the assessors’ level of comfort that the distribution shape and parameters assigned to the given parameter are appro-
priate given the existing state of knowledge.
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No WTP estimates are currently available for
CBD. However, most individuals diagnosed with
CBD will die from beryllium-related disease.(25) Be-
cause of a combination of high mortality and long-
term morbidity, applying life valuations to CBD may
be appropriate. Estimates for the statistical value of
life run as high as $16,300,000.(26) We include that fig-
ure as the highest value in our analysis, without dis-
counting for latency.
We estimate that laboratory analysis for Glu-69
will cost $100 per sample.(21) Allowing an extra $50
per sample for sample collection and shipment, we
estimate a total cost for Glu-69 testing of $150/sample
and assign bounds of $100 and $500 to allow for a
large degree of error. This parameter (Cgenotype) is rep-
resented by using a triangular distribution (Table I).
Voluntary preplacement screening would re-
quire some counseling for applicants testing Glu-691.
We suggest at least an hour’s worth of counseling for
each individual along with the production of written
materials for the applicant to take home. Our best es-
timate of this cost is $100 per Glu-691 applicant. We
assign a triangular distribution allowing possible
values in the range of half to double the primary esti-
mate (Table I).
The present value of the costs from 50 years of
additional LPTs in one individual (one extra test per
year over a lifetime) is estimated to be $2,200 per
Glu-691 individual using a 7% discount rate and $231
per LPT.(25) If a Glu-691 individual develops a positive
LPT during the fifth year of exposure and is immedi-
ately replaced by a Glu-692 individual, the dis-
counted cost of additional LPTs is about $700. The
true value is likely to lie somewhere between these
two estimates, so we represent CLPT by using a uni-
form distribution (Table I).
3.3.3. Predicted Risk Reduction Efficacy and
Preplacement Removal Probability
The efficacy of the proposed risk management
programs reflects how well they target and change
the behavior, exposure, or medical treatment of
Glu-691 individuals. In a required screening pro-
gram, essentially 100% of Glu-691 beryllium work
applicants would be replaced by Glu-692 individu-
als. With voluntary screening participation might be
somewhat lower, depending on the proportion of
workers consenting to a susceptibility test and de-
ciding to remove themselves from exposure when
test results are positive. Because participation in the
voluntary screening program is highly uncertain, we
assign a uniform distribution allowing for anywhere
between 0% and 100% removal likelihood for Glu-
691 applicants.
Medical or industrial hygiene intervention could
reduce disease rates through a different use of ge-
netic information. Rather than screening out geneti-
cally susceptible applicants before they are exposed
to beryllium, this type of intervention seeks to reduce
the disease risk or severity through targeted exposure
mitigation or heightened medical monitoring. We as-
sume that increasing LPT frequency would reduce
CBD risk by removing workers from beryllium expo-
sure earlier in the process of disease development.
No known evidence supports or contradicts the as-
sumed benefits of early detection of beryllium sensi-
tization, but it is reasonable based on other immune-
mediated disease models to assume that CBD risk
increases with exposure duration. Assuming a uniform
likelihood of CBD development in the time interval
between LPTs, increasing the LPT frequency from
once a year to twice a year would reduce the average
beryllium exposure duration by 3 months for sensi-
tized individuals. What effect if any this would have
on disease progression is unclear, but some evidence
indicates that CBD risk increases with exposure du-
ration.(27) Hypothesizing that the prevalence of dis-
ease might be linearly related to exposure duration
for Glu-691 individuals, detection and removal from
exposure 3 months early in a cohort with a 5-year la-
tency would reduce CBD prevalence by 5% among
individuals in that cohort assuming they are replaced
by workers who do not become sensitized. Alterna-
tively, the prevalence of disease could be propor-
tional to the postsensitization exposure duration, in
which case early detection would decrease the CBD
prevalence by 50%. Clearly a number of other models
could be formed, including the possibility that early
detection does not impact the likelihood of CBD de-
velopment. We assign a triangular distribution to this
parameter, with bounds of 0% and 50% and a mode
of 5% (Table I).
4. RESULTS
Predicted postintervention CBD risks are shown in
Table II. The risk estimates for 1% baseline prevalence
are graphed in Figure 1 for visual comparison. The
postintervention CBD risk is nearly linear with base-
line prevalence in the range of interest, so Figure 1 can
be used to visualize the approximate postintervention
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CBD risks at any baseline prevalence rate by rescal-
ing the y-axis from 0 to p. In a cohort with 1% base-
line CBD prevalence, the expected postintervention
prevalence rate for using the Glu-69 test as a required
job placement screen is 0.08%. A voluntary screening
program in the same cohort would be expected to re-
duce CBD prevalence to 0.6%, but this value is highly
sensitive to the participation rate. Use of the genetic
variant as a medical screen for semiannual in place of
annual lymphocyte proliferation testing yields a
0.8% mean predicted postintervention prevalence
for the example cohort. The 90% simulation inter-
vals, defined by the 5th and 95th percentiles of
Monte Carlo simulation output, are (0.02%, 0.2%)
for required screening, (0.6%, 1%) for increased
LPT frequency, and (0.2%, 1%) for voluntary
screening. These predicted postintervention risks
and the other analytical results depend heavily on
the parameter estimates in Table I and the underly-
ing model assumptions.
Net expected VOI per beryllium worker is esti-
mated across a range of baseline prevalence values
and CBD avoidance valuations (Table III). For most
current occupational prevalence rates and health val-
uations exceeding $1.45 million, the mean predicted
VOI exceeds zero, indicating an expected net social
gain for using the susceptibility biomarker in any of
the three proposed strategies. For example, at 10%
baseline CBD prevalence and $1.45 million per case
of CBD, the expected net per capita VOI for Glu-69
in required or voluntary screening increases to
$130,000 or $51,000, respectively. However, at low
baseline CBD prevalence rates and low health valua-
tions, the expected VOI for the three Glu-691 based
programs is negative, which indicates that the pro-
gram costs are expected to outweigh the benefits of
CBD reduction.
The baseline CBD prevalence and CBD valua-
tion for which the expected VOI is zero, or “cut-
points,” are shown as lines in Figure 2. Each Glu-69-
based risk management program is expected to be
cost effective only when the baseline prevalence and
selected health valuation produce a point to the right
of the respective cutpoint line. These graphs could be
expanded by adding VOI endpoints other than zero
or displaying cutpoints based on simulation bounds
(e.g., 5th and 95th percentiles) to indicate the effects
of uncertainty.
Sensitivity analysis was conducted for the three
risk management programs at 1% baseline preva-
lence and $1.45 million per CBD case avoided. Note
that p and Bd have the strongest influence by far on
the model results and the sensitivity analysis indi-
cates the relative importance of the remaining vari-
ables. Contribution to variance estimates based on
Spearman’s rank correlation indicate that for re-
quired screening about 94% of the VOI simulation
variance is associated with the sensitivity rate of CBD
to Glu-69 (Sn); the specificity rate (Sp) and Glu-69 fi-
nancial cost (Cgenotype) each contribute about 3% of the
Table II. Predicted Postintervention CBD Risk by Baseline 





0.1% Required screen 0.008% (0.001%, 0.020%)a
0.1% Increased LPT
frequency  0.08% (0.06%, 0.10%)
0.1% Voluntary screen  0.06% (0.02%, 0.10%)
1% Required screen  0.08% (0.02%, 0.20%)
1% Increased LPT 
frequency  0.8% (0.6%, 1.0%)
1% Voluntary screen  0.6% (0.2%, 1.0%)
10% Required screen  0.9% (0.2%, 2.1%)
10% Increased LPT
frequency  8.3% (6.3%, 9.7%)
10% Voluntary screen  6.5% (1.6%, 9.7%)
a First value indicates expected value of CBD risk; range in paren-
theses indicates 90% simulation interval as defined by the 5th
and 95th percentiles of Monte Carlo simulation results. These
values depend on hypothetical models and subjective parameter
estimates shown in Table I.
Fig. 1. Simulated post-intervention CBD risk at 1% baseline
prevalence. 50% simulation intervals are displayed as boxes and
90% simulation intervals are shown as outer lines. These values de-
pend on hypothetical models and subjective parameter estimates
shown in Table I.
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variance. For voluntary screening 98% of the VOI
simulation variance is attributable to uncertainty re-
garding the removal rate for voluntary screening
(wvolunteer). For increased LPT frequency in Glu-691
workers, 98% of the variance in simulated VOI is
associated with the risk-reduction efficacy of in-
creased LPT frequency (eLPT), and 1% of the vari-
ance is associated with the cost of additional LPT
testing (CLPT). Other variables contribute mini-
mally (,1%) to the total uncertainty regarding
VOI for any of these three programs.
5. DISCUSSION
Our analysis indicates that the expected health
benefits of a Glu-69-based required screening pro-
gram for machinists at typical baseline prevalence
levels far outweigh the expected financial costs for
most health valuations. If an a priori judgment is
made that the qualitative social and ethical risks of
required screening are too burdensome or if required
genetic screening is determined to be illegal,(28) other
Glu-69-based risk management programs may be






Value of CBD avoidance
$12,200  $240,000  $1,450,000 $16,300,000
0.1% Required screen 2$350 (2610, 2180)a 2$140 (2400, 40) $970 (680, 1,200) $15,000 (13,000, 16,000)
0.1% Increased LPT frq. 2$690 (21,000, 2410) 2$650 (2990, 2370) 2$440 (2840, 240) $2,100 (2180, 5,400)
0.1% Voluntary screen 2$330 (2560, 2180) 2$250 (2450, 270) $210 (2280, 870) $5,700 (220, 14,000)
1% Required screen 2$250 (2510, 280) $1,800 (1,500, 2,100) $13,000 (11,000, 14,000) $150,000 (130,000, 160,000)
1% Increased LPT frq. 2$680 (21,000, 2400) 2$290 (2790, 270) $1,800 (2230, 4,700) $28,000 (4,800, 61,000)
1% Voluntary screen 2$290 (2500, 2150) $560 (2220, 1,700) $5,100 (120, 12,000) $60,000 (4,900, 140,000)
10% Required screen $710 (410, 950) $21,000 (19,000, 23,000) $130,000 (110,000, 140,000) $1,500,000 (1,300,000, 1,600,000)
10% Increased LPT frq. 2$570 (2980, 2180) $3,300 (10, 8,100) $24,000 (4,100, 52,000) $280,000 (54,000, 610,000)
10% Voluntary screen $70 (2320, 630) $8,000 (360, 20,000) $51,000 (3,800, 120,000) $570,000 (49,000, 1,400,000)
a First value indicates expected value in dollars per beryllium worker; range in parentheses indicates 90% simulation interval as defined by
the 5th and 95th percentiles of Monte Carlo simulation results. These values depend on hypothetical models and subjective parameter es-
timates shown in Table I.
Fig. 2. Values of p and Bd that produce an expected VOI of $0 for each GLU-69-based intervention. Each line shows the cutpoints for a
single intervention type based on possible combinations of the two key parameters, holding all other parameters at their expected values.
Regions above each cutpoint line indicate combinations of p and Bd expected to result in a positive VOI for that particular GLU-69-based
intervention. Regions below each cutpoint line indicate parameter values resulting in a negative expected VOI. All values depend on hypo-
thetical models and subjective parameter estimates shown in Table I.
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more appropriate. Voluntary placement, for example,
may be as nearly effective as required screening in re-
ducing disease. The major risk associated with this ap-
proach is the possibility that few Glu-691 workers will
decide to get tested or to avoid placement in beryllium-
exposed job tasks. However, even if every worker de-
cides to get tested for susceptibility but nobody with
Glu-691 decides to act on the results, the financial
costs are minimal (z$290/worker). Furthermore,
even if only one of every hundred Glu-691 applicants
decides to remove themselves from exposure, the ex-
pected value of the health benefits will still exceed the
program costs at health valuations greater than
$500,000 per CBD case.
Indirect benefits of biomarker development and
use exist but have not been evaluated in this model.
The identification of the polymorphism and develop-
ment of the Glu-69 test, for example, may ultimately
allow understanding of the mechanisms underlying
CBD and thus lead perhaps to better prevention or
treatment options.(20) Medical surveillance programs
designed around the susceptibility biomarker might
similarly lead to new insights regarding CBD etiol-
ogy. Although it may not be appropriate to include
these impacts in deciding whether or not to broadly
implement a risk management program based on ge-
netic susceptibility, they are important considerations
when targeting biomarker research.
5.1. Other Risk Management Options
Not all risk management options have been eval-
uated here, nor have combinations of the three op-
tions. Process changes, personal protective equipment,
and limitations on exposure duration are common
methods used in industrial hygiene practice to reduce
exposure.(29) Indeed, DOE has recently introduced
substantial exposure reduction activities as part of a
suite of hazard mitigation and communication activi-
ties intended to reduce CBD incidence among its
workers.(30) Because the dose–response relationship is
unclear, whether exposure reductions beyond the
current standard will lead to substantially reduced
CBD incidence is uncertain. Although it is prudent to
assume that further reductions in exposure concen-
tration are likely to reduce disease incidence, for be-
ryllium there is little direct evidence to support or
contradict this assumption.
Quantitative dose–response models for beryllium-
induced CBD are currently unavailable. Such a
model could easily be incorporated into this analysis
and would provide a means of estimating the risk re-
duction and VOI for beryllium exposure controls.
Here we chose not to consider the effectiveness of ex-
posure reductions but rather to limit our analysis to
the utility of the Glu-69 test at specific baseline CBD
prevalence levels. If a Glu-69 genetic screening ap-
proach is combined with exposure reductions to all
workers, the value of the genetic information de-
pends on the baseline prevalence following the expo-
sure reduction. For example, current CBD preva-
lence among beryllium machinists has been reported
as approximately 10% for one cohort.(23) If additional
exposure controls in these machinists were expected
to lead to a 90% reduction in risk, the new baseline
prevalence in this cohort would be 1%, and the ex-
pected VOI for the voluntary Glu-69 program
would decrease from $8,000 to $560 per beryllium
machinist based on $240,000 per CBD case avoided
(Table III).
Other programs might be considered in addition
to those heightened medical monitoring options eval-
uated here. For example, the interval between succes-
sive LPTs might be changed to other values, and
when warranted, other clinical tests could be used to
ascertain disease status before the appearance of
frank CBD. Although the possibility has not been
quantitatively evaluated here, any application of Glu-
69 genetic screening might indirectly induce some
Glu-691 beryllium workers to reduce their own beryl-
lium exposures, thereby indirectly increasing the util-
ity of the program. However, the disease reduction
benefits of early detection of sensitization or disease
are unlikely to be greater than the benefits of re-
quired or voluntary preplacement screening, and the
financial costs of heightened medical monitoring are
relatively high. Nonetheless, heightened medical
monitoring targeted to Glu-691 workers may be su-
perior to not using Glu-69-based genetic testing at
current occupational CBD prevalence rates. In addi-
tion, heightened medical monitoring may be the only
genetically based intervention available to former
beryllium workers.
We have not evaluated the possibility of using
multiple genetic polymorphisms in screening. Poly-
morphisms other than the Glu-69 substitution have
been associated with CBD, albeit none have demon-
strated as high sensitivity or specificity for predicting
CBD. Use of information derived from multiple poly-
morphisms might increase the sensitivity and speci-
ficity of genetically based screening for CBD, and
determination of possible genetic linkages would
provide insight into whether the Glu-69 polymor-
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phism is causally implicated in disease onset and
progression.
Richeldi et al.(2) investigated multiple polymor-
phisms in the HLA-DPB1 gene after a screening
study demonstrated no strong associations with poly-
morphisms in the HLA-DR and -DQ genes. They re-
port that an aspartic acid–glutamic acid substitution
for alanine-alanine at position 55–56 showed signifi-
cant association with disease (79% sensitivity and
59% specificity). Because individual data were not
provided in the publication, however, whether indi-
viduals with both polymorphisms exhibited greater
disease prevalence was unclear. A concomitant anal-
ysis of genetic linkage between Glu-69 and polymor-
phic sites within HLA-DRB4 and TNFB demon-
strated no association with CBD.(2)
In a study of genetic polymorphisms associated
with beryllium hypersensitivity, Stubbs et al.(31) exam-
ined HLA-DRB1, -DRB3, -DRB4, -DRB5, and -DPB1.
They observed a significant association between be-
ryllium sensitization and the HLA-DPB1 Glu-69
polymorphism, supporting the observations of Rich-
eldi et al.(2) In addition, they observed that five spe-
cific polymorphisms in HLA-DRB1 were associated
with susceptibility to beryllium sensitization and that
four others within the same gene were associated
with protection. Polymorphisms associated with re-
duced prevalence of sensitization were also observed
within HLA-DRB3 and -DRB5. Whether these poly-
morphisms are associated with development of CBD
has not been reported, and genetic linkage between
HLA-DP genes and other MHC class II genes is
low.(32) Finally, unpublished analyses by Saltini et al.
reportedly demonstrate a significant association be-
tween CBD and polymorphisms in TNF-a; however,
the association is reportedly weaker than that ob-
served with Glu-69,(8) and no information is currently
available regarding disease prevalence among indi-
viduals with both polymorphisms.
5.2. Social Implications and Ethics 
of Genetic Screening
If a decisionmaker decides that the social and
ethical risks of required Glu-69 screening should be
quantified and weighed against the financial and
health risks, Eq. 1 can be expanded to include all of
those risks. Because of the difficulty in assigning
value to social risks, we have chosen to treat them
qualitatively instead of quantitatively in this analysis.
For this reason we have also calculated VOI sepa-
rately for each risk management option, rather than
taking the more typical approach of optimizing be-
fore the VOI calculation.(33) We feel that our approach
may be more informative to decisionmakers, particu-
larly when they might wish to select a “suboptimal”
risk management option based on factors external to
the quantitative analysis.
Many authors have pointed out the social and
ethical hazards of occupational genetic screening.(34)
These hazards include potential loss of employment,
benefits, employability, insurability, and privacy for
individuals who are genetically susceptible but may
not develop disease after beryllium exposure. Be-
cause of the potential for these negative impacts, and
because the majority of beryllium-exposed Glu-691
individuals will not develop CBD, some beryllium re-
searchers have recommended that Glu-69 not be
used for employment screening.(23) We do not intend
to belittle these concerns, but when the health risks
are substantial the ethical hazards of failing to act are
also worthy of consideration. This ethical hazard is
heightened in this case by the uncertainty regarding
the dose–response relationship for CBD, the absence
of a complete cure, and the complications often en-
countered when using long-term immunosuppressive
therapy as is frequently required for CBD. Although
the current 2 mg/m3 standard is clearly not protective
of all workers, further beryllium exposure reduc-
tions are not guaranteed to substantially reduce
CBD incidence because of the exquisite susceptibil-
ity of some individuals. Hence, other options must
be considered for use in conjunction with improved
exposure controls.
The social risks of taking action on the basis of
genetic test results can be mitigated to some extent.
For example, DOE has directed that its workers test-
ing positive for sensitization to beryllium be removed
from job tasks with known beryllium exposure but re-
tain full employment and benefits for some time after
diagnosis.(30) A similar rule could be applied to cur-
rent workers testing positive for genetic susceptibility
to beryllium, though this would increase the costs of
the screening program and thereby reduce the ex-
pected VOI. In addition, federal legislation disallow-
ing the use of genetic susceptibility tests by insurance
companies and preventing inappropriate use of ge-
netic screening by employers has been proposed.(35,36)
Although this issue is highly contentious and will
likely be discussed for years to come, legal safeguards
on the availability and use of genetic information
might mitigate some of the concerns raised by bio-
ethicists. For example, employers could hire an inde-
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pendent laboratory to conduct confidential genetic
testing and provide confidential counseling to current
and prospective beryllium workers. This approach
would encourage individuals to get tested by protect-
ing their privacy but would increase screening costs
for employers. Revised estimates of the VOI for ex-
panded programs such as these could be obtained by
using our model equations.
The success of any voluntary screening program
depends on trust. Participation rates can increase
over time as a program becomes established and
gains credibility. One study reported that over 99.9%
of Maryland parents consented to newborn phe-
nylketonuria screening for medical intervention after
the state repealed a required screening law.(37) Any-
thing close to this degree of participation could only
be achieved in the occupational setting by carefully
addressing the privacy and job security concerns of
those tested and through well-conceived risk commu-
nication. Although previous surveys found many
people reluctant to share genetic information with
employers,(38) it is reasonable to believe that some be-
ryllium workers would give informed consent to sus-
ceptibility testing and remove themselves from beryl-
lium work on the basis of the results. Given the health
risks, we believe that beryllium workers should at
least be provided with information about the poten-
tial uses of the test.
5.3. Data Needs and Suggestions 
for Future Research
The health valuation for CBD is clearly the most
important aspect of this model in terms of impact on
the predicted VOI. Readers are likely to have quite
different opinions on the most appropriate value of
Bd, and for policy makers to select an appropriate
value may be difficult. Although some of these dis-
crepancies could be resolved by COI and WTP studies
conducted specifically for CBD, further research is
unlikely to resolve basic differences of opinion.
Of the other variables in the model, several
stand out as crucial areas for additional research. The
voluntary participation rate is unknown as we are un-
aware of such a genetically based occupational
screening model in current use. Even were data avail-
able for another genetic screen, how applicable these
data would be to the particular case of Glu-69 and
CBD is questionable. The specific contextual factors
are likely to strongly influence the participation rate
for such a program; thus a small-scale pilot study to
preliminarily estimate the parameter would be re-
quired. We suggest that Glu-69 may be appropriate
for such a pilot study, on the basis of the VOI analysis
conducted here.
The medical value of higher LPT frequency is
also open to question and is represented by a wide
range of possibilities in the present model. A detailed
quantitative model of beryllium sensitization and
CBD progression is needed for this and other aspects
of our model, but existing models are mostly qualita-
tive and still open to debate. Future work should in-
clude the development and testing of more detailed
disease models for CBD, particularly those that take
both genetic status and beryllium exposure charac-
teristics into account. For example, we have hypothe-
sized that the sensitivity and specificity rates are inde-
pendent of baseline CBD prevalence by using a
relatively simple model for the interaction of genetics
and environment in producing CBD. More cohort
study data would allow for the exploration of this
model and alternative hypotheses.
6. CONCLUSIONS
The Glu-69 genetic biomarker, when used as a
required or voluntary screen for occupational place-
ment in beryllium-contaminated areas, is expected to
be cost-effective in mitigating CBD in typical cohorts
when CBD valuation is above $100,000 per case. At
lower valuations and lower baseline disease preva-
lence rates, cost-effectiveness decreases. However,
genetic screening has significant ethical and legal im-
plications that may prevent implementation. Volun-
tary screening may be nearly as cost effective as re-
quired screening and is more likely to be accepted by
stakeholders, but predicting the participation rate is
difficult. Increasing the frequency of the LPT from
once a year to twice a year for Glu-691 individuals
may also decrease disease prevalence at a reasonable
cost but is predicted to be less effective than either of
the screening programs.
We recommend a dialogue among stakeholders
about the use of voluntary Glu-69 testing for beryl-
lium work applicants or existing workers expected to
enter areas with known beryllium contamination. If
workers’ privacy and employability concerns are ad-
dressed, voluntary screening can achieve significant
disease reduction without undesirable social conse-
quences. Heightened medical monitoring may still be
worthwhile, perhaps in conjunction with voluntary
screening, but is not as amenable to privacy protec-
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tion as voluntary genetic testing conducted by an out-
side party.
Many more biomarkers are available today than
are actually used in clinical, occupational, or environ-
mental risk management. Highly sensitive and spe-
cific biomarkers are clearly valid for practice, but less
obvious biomarkers may also offer significant oppor-
tunities for disease reduction. Tools such as decision
analysis and VOI analysis can assist in discriminating
between good and poor biomarker opportunities by
providing information about the predicted costs and
benefits of using biomarkers in specific applications.
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APPENDIX: ESTIMATION OF POSITIVE AND 
NEGATIVE PREDICTIVE VALUES FROM 
SENSITIVITY AND SPECIFICITY RATES
The relationship between screening biomarkers
and disease can be reported in many different ways. Ep-
idemiologists often use positive and negative predictive
values (PV1 and PV2) as one set of measures indicating
the efficacy of binary screening tests for predicting bi-
nary disease states. Predictive values can be directly ob-
tained only from cohort studies. Predictive values are
simply conditional probabilities (Pr) of the test re-
sults accurately reflecting the eventual disease state:
PV1 5 Pr[D1|T1] (8)
PV2 5 Pr[D2|T2] (9)
where D1 is diseased and D2 is disease-free, and T1 is
a positive screening result and T2 is a negative screen-
ing result. Sensitivity (Sn) and specificity (Sp) are dif-
ferent measures of screening efficacy and can be mea-
sured in both case-control and cohort studies. Sn and
Sp are the reverse conditional probabilities of PV1
and PV2:
Sn 5 Pr[T1|D1] (10)
Sp 5 Pr[T2|D2] (11)
The proportion of the population screening positive
( f ) is estimated(39) from Sn, Sp, and the baseline dis-
ease risk ( p) using Bayes’ Rule:
f 5 Pr[T1]
5 Pr[T1, D1] 1 Pr[T1, D2]
5 Pr[T1|D1]Pr[D1] 1 Pr[T1|D2] Pr[D2]
5 Sn p 1 (12 Sp) (12 p). (12)
PV2 and PV1 are then estimated from Sn, Sp, f, and p
in a similar manner:
PV1 5 Pr[D1|T1]
5 Pr[D1, T1] / Pr[T1]
5 Pr[T1|D1] Pr[D1]/Pr[T1]
5 Sn p/f (13)
PV2 5 Pr[D2|T2]
5 Pr[D2, T2] / Pr[T2]
5 Pr[T2|D2] Pr[D2] / Pr[T2]
5 Sp (1 2 p) / (1 2 f ). (14)
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